


Twitter Thread by BharatBiotech

 **BharatBiotech**
@BharatBiotech



COVAXIN® Proven SAFE in India's Largest Efficacy Trial. Final Phase-3 Pre-Print Data Published on <https://t.co/JJh9n3aB6V>

ANNOUNCEMENT

RESULTS FROM FINAL ANALYSIS PHASE-3 STUDY:

COVAXIN[®] WITH UNPARALLELED SAFETY



LARGEST EFFICACY TRIAL IN INDIA
Across 25 trial sites; 18-98 years of age



Against asymptomatic
COVID-19 transmission



Against mild, moderate and
severe COVID-19 disease



Against B.1.617.2
Delta Variant



Against severe COVID-19 disease
reducing hospitalizations



WELL TOLERATED with minimal adverse events post-immunization

PREPRINT VERSION AVAILABLE ON [medRxiv](#)

25

YEARS OF INNOVATION


BHARAT
BIOTECH

10 PUBLICATIONS



DATA TRANSPARENCY

Lead Innovation